I get that but if you can't someone normotensive or they are requiring more and more pressor support, then it doesn't matter what you use, the patient has a dismal prognosis. It's one thing if angiotensin was compared against norepi and found to have any advantage but right now, it's being used as a phenylephrine alternative in select cases and as you know in the MICU, once you are on 3 pressors and faltering, your prognosis is dismal.
If giapreza was shown to have an advantage upfront over norepi or vs vaso, then yes, it would have been a welcome change. Right now, it looks like it's only useful in select cases (eg as above).